Skip to main content

Rabbit Recombinant Monoclonal PLK1 phospho T210 antibody. Suitable for Dot, WB, IHC-P and reacts with Human, Mouse samples. Cited in 17 publications.

Be the first to review this product! Submit a review

Images

Western blot - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (AB155095), expandable thumbnail
  • Dot Blot - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (AB155095), expandable thumbnail
  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (AB155095), expandable thumbnail
  • Western blot - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (AB155095), expandable thumbnail
  • Western blot - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (AB155095), expandable thumbnail

Publications

Key facts

Isotype
IgG
Host species
Rabbit
Storage buffer

Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA

Form
Liquid
Clonality
Monoclonal

Immunogen

  • The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

Select an application
Product promiseTestedExpectedPredictedNot recommended
DotWBIHC-P
Human
Tested
Tested
Tested
Mouse
Expected
Tested
Expected

Tested
Tested

Species
Human
Dilution info
-
Notes

Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

Expected
Expected

Species
Mouse
Dilution info
Use at an assay dependent concentration.
Notes

-

Tested
Tested

Species
Human
Dilution info
1/1000
Notes

For unpurified use at 1/1000 - 1/10000.

Species
Mouse
Dilution info
1/1000
Notes

For unpurified use at 1/1000 - 1/10000.

Tested
Tested

Species
Human
Dilution info
1/500
Notes

For unpurified use at 1/100 - 1/250.

Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

Expected
Expected

Species
Mouse
Dilution info
Use at an assay dependent concentration.
Notes

-

Associated Products

Select an associated product type

14 products for Alternative Product

Target data

Function

Serine/threonine-protein kinase that performs several important functions throughout M phase of the cell cycle, including the regulation of centrosome maturation and spindle assembly, the removal of cohesins from chromosome arms, the inactivation of anaphase-promoting complex/cyclosome (APC/C) inhibitors, and the regulation of mitotic exit and cytokinesis (PubMed:11202906, PubMed:12207013, PubMed:12447691, PubMed:12524548, PubMed:12738781, PubMed:12852856, PubMed:12939256, PubMed:14532005, PubMed:14734534, PubMed:15070733, PubMed:15148369, PubMed:15469984, PubMed:16198290, PubMed:16247472, PubMed:16980960, PubMed:17081991, PubMed:17351640, PubMed:17376779, PubMed:17617734, PubMed:18174154, PubMed:18331714, PubMed:18418051, PubMed:18477460, PubMed:18521620, PubMed:18615013, PubMed:19160488, PubMed:19351716, PubMed:19468300, PubMed:19468302, PubMed:19473992, PubMed:19509060, PubMed:19597481, PubMed:23455478, PubMed:23509069, PubMed:28512243, PubMed:8991084). Polo-like kinase proteins act by binding and phosphorylating proteins that are already phosphorylated on a specific motif recognized by the POLO box domains (PubMed:11202906, PubMed:12207013, PubMed:12447691, PubMed:12524548, PubMed:12738781, PubMed:12852856, PubMed:12939256, PubMed:14532005, PubMed:14734534, PubMed:15070733, PubMed:15148369, PubMed:15469984, PubMed:16198290, PubMed:16247472, PubMed:16980960, PubMed:17081991, PubMed:17351640, PubMed:17376779, PubMed:17617734, PubMed:18174154, PubMed:18331714, PubMed:18418051, PubMed:18477460, PubMed:18521620, PubMed:18615013, PubMed:19160488, PubMed:19351716, PubMed:19468300, PubMed:19468302, PubMed:19473992, PubMed:19509060, PubMed:19597481, PubMed:23455478, PubMed:23509069, PubMed:28512243, PubMed:8991084). Phosphorylates BORA, BUB1B/BUBR1, CCNB1, CDC25C, CEP55, ECT2, ERCC6L, FBXO5/EMI1, FOXM1, KIF20A/MKLP2, CENPU, NEDD1, NINL, NPM1, NUDC, PKMYT1/MYT1, KIZ, MRE11, PPP1R12A/MYPT1, POLQ, PRC1, RACGAP1/CYK4, RAD51, RHNO1, SGO1, STAG2/SA2, TEX14, TOPORS, p73/TP73, TPT1, WEE1 and HNRNPU (PubMed:11202906, PubMed:12207013, PubMed:12447691, PubMed:12524548, PubMed:12738781, PubMed:12852856, PubMed:12939256, PubMed:14532005, PubMed:14734534, PubMed:15070733, PubMed:15148369, PubMed:15469984, PubMed:16198290, PubMed:16247472, PubMed:16980960, PubMed:17081991, PubMed:17218258, PubMed:17351640, PubMed:17376779, PubMed:17617734, PubMed:18174154, PubMed:18331714, PubMed:18418051, PubMed:18477460, PubMed:18521620, PubMed:18615013, PubMed:19160488, PubMed:19351716, PubMed:19468300, PubMed:19468302, PubMed:19473992, PubMed:19509060, PubMed:19597481, PubMed:22325354, PubMed:23455478, PubMed:23509069, PubMed:25986610, PubMed:26811421, PubMed:28512243, PubMed:37440612, PubMed:37674080, PubMed:8991084). Plays a key role in centrosome functions and the assembly of bipolar spindles by phosphorylating KIZ, NEDD1 and NINL (PubMed:16980960, PubMed:19509060). NEDD1 phosphorylation promotes subsequent targeting of the gamma-tubulin ring complex (gTuRC) to the centrosome, an important step for spindle formation (PubMed:19509060). Phosphorylation of NINL component of the centrosome leads to NINL dissociation from other centrosomal proteins (PubMed:12852856). Involved in mitosis exit and cytokinesis by phosphorylating CEP55, ECT2, KIF20A/MKLP2, CENPU, PRC1 and RACGAP1 (PubMed:12939256, PubMed:16247472, PubMed:17351640, PubMed:19468300, PubMed:19468302). Recruited at the central spindle by phosphorylating and docking PRC1 and KIF20A/MKLP2; creates its own docking sites on PRC1 and KIF20A/MKLP2 by mediating phosphorylation of sites subsequently recognized by the POLO box domains (PubMed:12939256, PubMed:17351640). Phosphorylates RACGAP1, thereby creating a docking site for the Rho GTP exchange factor ECT2 that is essential for the cleavage furrow formation (PubMed:19468300, PubMed:19468302). Promotes the central spindle recruitment of ECT2 (PubMed:16247472). Plays a central role in G2/M transition of mitotic cell cycle by phosphorylating CCNB1, CDC25C, FOXM1, CENPU, PKMYT1/MYT1, PPP1R12A/MYPT1 and WEE1 (PubMed:11202906, PubMed:12447691, PubMed:12524548, PubMed:19160488). Part of a regulatory circuit that promotes the activation of CDK1 by phosphorylating the positive regulator CDC25C and inhibiting the negative regulators WEE1 and PKMYT1/MYT1 (PubMed:11202906). Also acts by mediating phosphorylation of cyclin-B1 (CCNB1) on centrosomes in prophase (PubMed:12447691, PubMed:12524548). Phosphorylates FOXM1, a key mitotic transcription regulator, leading to enhance FOXM1 transcriptional activity (PubMed:19160488). Involved in kinetochore functions and sister chromatid cohesion by phosphorylating BUB1B/BUBR1, FBXO5/EMI1 and STAG2/SA2 (PubMed:15148369, PubMed:15469984, PubMed:17376779, PubMed:18331714). PLK1 is high on non-attached kinetochores suggesting a role of PLK1 in kinetochore attachment or in spindle assembly checkpoint (SAC) regulation (PubMed:17617734). Required for kinetochore localization of BUB1B (PubMed:17376779). Regulates the dissociation of cohesin from chromosomes by phosphorylating cohesin subunits such as STAG2/SA2 (By similarity). Phosphorylates SGO1: required for spindle pole localization of isoform 3 of SGO1 and plays a role in regulating its centriole cohesion function (PubMed:18331714). Mediates phosphorylation of FBXO5/EMI1, a negative regulator of the APC/C complex during prophase, leading to FBXO5/EMI1 ubiquitination and degradation by the proteasome (PubMed:15148369, PubMed:15469984). Acts as a negative regulator of p53 family members: phosphorylates TOPORS, leading to inhibit the sumoylation of p53/TP53 and simultaneously enhance the ubiquitination and subsequent degradation of p53/TP53 (PubMed:19473992). Phosphorylates the transactivation domain of the transcription factor p73/TP73, leading to inhibit p73/TP73-mediated transcriptional activation and pro-apoptotic functions. Phosphorylates BORA, and thereby promotes the degradation of BORA (PubMed:18521620). Contributes to the regulation of AURKA function (PubMed:18615013, PubMed:18662541). Also required for recovery after DNA damage checkpoint and entry into mitosis (PubMed:18615013, PubMed:18662541). Phosphorylates MISP, leading to stabilization of cortical and astral microtubule attachments required for proper spindle positioning (PubMed:23509069). Together with MEIKIN, acts as a regulator of kinetochore function during meiosis I: required both for mono-orientation of kinetochores on sister chromosomes and protection of centromeric cohesin from separase-mediated cleavage (By similarity). Phosphorylates CEP68 and is required for its degradation (PubMed:25503564). Regulates nuclear envelope breakdown during prophase by phosphorylating DCTN1 resulting in its localization in the nuclear envelope (PubMed:20679239). Phosphorylates the heat shock transcription factor HSF1, promoting HSF1 nuclear translocation upon heat shock (PubMed:15661742). Phosphorylates HSF1 also in the early mitotic period; this phosphorylation regulates HSF1 localization to the spindle pole, the recruitment of the SCF(BTRC) ubiquitin ligase complex induicing HSF1 degradation, and hence mitotic progression (PubMed:18794143). Regulates mitotic progression by phosphorylating RIOK2 (PubMed:21880710). Through the phosphorylation of DZIP1 regulates the localization during mitosis of the BBSome, a ciliary protein complex involved in cilium biogenesis (PubMed:27979967). Regulates DNA repair during mitosis by mediating phosphorylation of POLQ and RHNO1, thereby promoting POLQ recruitment to DNA damage sites (PubMed:37440612, PubMed:37674080). Phosphorylates ATXN10 which may play a role in the regulation of cytokinesis and may stimulate the proteasome-mediated degradation of ATXN10 (PubMed:21857149).

Alternative names

Recommended products

Rabbit Recombinant Monoclonal PLK1 phospho T210 antibody. Suitable for Dot, WB, IHC-P and reacts with Human, Mouse samples. Cited in 17 publications.

Key facts

Isotype
IgG
Form
Liquid
Clonality
Monoclonal
Immunogen
  • The exact immunogen used to generate this antibody is proprietary information.
Clone number
EPNCIR167
Purification technique
Affinity purification Protein A
Concentration
Loading...

Storage

Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C

Notes

This antibody was developed as part of a collaboration between the National Cancer Institute's Center for Cancer Research and the lab of Kyung Lee. View antibodies from NCI Center for Cancer Research Collaboration.

Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Rat: We have preliminary internal testing data to indicate this antibody may not react with this species. Please contact us for more information.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

12 product images

  • Western blot - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (ab155095), expandable thumbnail

    Western blot - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (ab155095)

    PLK1 (phospho T210) Western blot staining using rabbit Anti-PLK1 (phospho T210) antibody

    antibody used for ab155095 is purified batch

    All lanes: Western blot - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (ab155095) at 1/1000 dilution

    Lane 1: Hela (Human cervix adenocarcinoma epithelial cell) whole cell lysates at 15 µg with NFDM/TBST

    Lane 2: Hela (Human cervix adenocarcinoma epithelial cell) treated with thymidine (2mM, 16 h) then with nocodazole (10nM, 24h) Whole cell lysates at 15 µg with NFDM/TBST

    Lane 3: Hela (Human cervix adenocarcinoma epithelial cell) treated with thymidine (2mM, 16 h) then with nocodazole (10nM, 24h) Whole cell lysates, then the membrane was incubated with phosphatase at 15 µg with NFDM/TBST

    Secondary

    All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/20000 dilution

    Predicted band size: 68 kDa

    Observed band size: 68 kDa

    Exposure time: 10s

  • Dot Blot - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (ab155095), expandable thumbnail

    Dot Blot - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (ab155095)

    Anti-PLK1 (phospho T210) antibody [EPNCIR167] (ab155095) Dot Blot. Primary ab dilution 1:1000, Secondary ab description and code (ab id)Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (Goat Anti-Rabbit IgG H&L (HRP) ab97051), Secondary ab dilution 1:100,000. Blocking buffer and concentration 5% NFDM/TBST, Diluting buffer and concentration 5% NFDM /TBST. Lane 1:PLK1 (pT210) phospho peptide, Lane 2: PLK1 non-phospho peptide, Exposure time 10 seconds. Note: antibody used for ab155095 is purified batch.

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (ab155095), expandable thumbnail

    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (ab155095)

    ab155095 staining PLK1 (phospho T210) in Human colon tissue sections by Immunohistochemistry (IHC-P - paraformaldehyde-fixed, paraffin-embedded sections). Tissue was fixed and paraffin-embedded, antigen retrieval was by heat mediation in Tris/EDTA buffer pH9. Samples were incubated with primary antibody (1/500). An undiluted HRP-conjugated anti-rabbit IgG was used as the secondary antibody. Tissue counterstained with Hematoxylin. PBS was used in the negative control rather than the Primary antibody.

  • Western blot - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (ab155095), expandable thumbnail

    Western blot - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (ab155095)

    All lanes: Western blot - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (ab155095) at 1/1000 dilution

    Lane 1: HeLa cell lysate at 10 µg

    Lane 2: HeLa cell lysate post treatment with Nocodazole at 10 µg

    Secondary

    All lanes: Goat Anti-Rabbit IgG, (H+L), HRP-conjugated at 1/1000 dilution

    Predicted band size: 68 kDa

  • Western blot - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (ab155095), expandable thumbnail

    Western blot - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (ab155095)

    All lanes: Western blot - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (ab155095) at 1/1000 dilution

    Lane 1: HeLa cell lysate, untreated at 10 µg

    Lane 2: HeLa cell lysate, treated with calyculin A at 10 µg

    Secondary

    All lanes: Goat anti-rabbit HRP at 1/2000 dilution

    Predicted band size: 68 kDa

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (ab155095), expandable thumbnail

    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (ab155095)

    Immunohistochemical analysis of paraffin-embedded Human colon tissue labeling PLK1 with ab155095, unpurified, at 1/100 dilution.

    Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (ab155095), expandable thumbnail

    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (ab155095)

    Immunohistochemical analysis of paraffin-embedded Human gastroic carcinoma tissue labeling PLK1 with ab155095, unpurified, at 1/100 dilution.

    Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (ab155095), expandable thumbnail

    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (ab155095)

    Immunohistochemical analysis of paraffin embedded Human thyroid gland carcinoma tissue using ab155095, unpurified, showing +ve staining.

    Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (ab155095), expandable thumbnail

    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (ab155095)

    Immunohistochemical analysis of paraffin embedded Human cervical carcinoma tissue using ab155095, unpurified, showing +ve staining.

    Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (ab155095), expandable thumbnail

    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (ab155095)

    Immunohistochemical analysis of paraffin embedded Human placenta tissue using ab155095, unpurified, showing +ve staining.

    Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

  • Western blot - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (ab155095), expandable thumbnail

    Western blot - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (ab155095)

    Blocking buffer and concentration: 5% NFDM/TBST.

    Diluting buffer and concentration: 5% NFDM/TBST.

    Exposure Time: Lane 1-2: 40 seconds, Lane 3: 3 seconds and Lane 4: 180 seconds.

    Anti-GAPDH antibody [EPR16891] - Loading Control ab181602 was used as a loading control.

    All lanes: Western blot - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (ab155095) at 1/1000 dilution

    Lane 1: HeLa (Human cervix adenocarcinoma epithelial cell) (RIPA) whole cell lysate at 20 µg

    Lane 2: NIH/3T3 (Mouse embryonic fibroblast) (RIPA) whole cell lysate at 20 µg

    Lane 3: Mouse testis (RIPA) lysate at 20 µg

    Lane 4: Mouse colon (RIPA) lysate at 20 µg

    Secondary

    All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/20000 dilution

    Predicted band size: 68 kDa

    Observed band size: 68 kDa

  • Western blot - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (ab155095), expandable thumbnail

    Image collected and cropped by CiteAb under a CC-BY license from the publication

    Western blot - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (ab155095)

    PLK1 (phospho T210) western blot using anti-PLK1 (phospho T210) antibody [EPNCIR167] ab155095. Publication image and figure legend from Liccardi, G., Ramos Garcia, L., et al., 2019, Mol Cell, PubMed 30598363.


    ab155095 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab155095 please see the product overview.

    RIPK1 Negatively Regulates PLK1(A) Schematic representation of RIPK1- and Casp8-mediated regulation of PLK1.(B) Immunoblots of primary intestinal organoids from two Ripk1fl/fl,IEC-creERTM animals. Organoids were treated with ETOH (vehicle control) or 4-OHT, synchronized with CDK1i, and released into media. Cells were lysed and analyzed by immunoblot with the indicated antibodies.(C) In situ PLA detection of PLK1 and RIPK1 in HT1080 cells, following Casp8 or Plk1 siRNA. Green dots indicate PLA signals between PLK1 and RIPK1. Graph shows quantifications of RIPK1/PLK1 PLA speckles (mean ± SD). 15 cells were counted for each condition. Scale bars: 10 μm.(D and E) In vitro cleavage assay. Purified HA-tagged PLK1 construct and recombinant Casp8 were incubated for 1 h. Immunoblots analysis using the indicated antibodies is shown.(F) HT1080 cells were synchronized with CDK1i and released in media containing the indicated drugs. Lysates from asynchronous or synchronized HT1080 cells were immunoprecipitated with anti-Casp8 antibody. Immunoblot analysis using the indicated antibodies is shown.(G) In situ PLA detection of Casp8/RIPK1 in CDK1i-synchronized and released HT1080 cells treated with the indicated agents. Green dots indicate PLA speckles. Scale bars: 10 μm.

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com